Patents by Inventor Danja Grossbach

Danja Grossbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220257547
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 18, 2022
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Patent number: 11344519
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 31, 2022
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Publication number: 20210113504
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Patent number: 10905667
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: February 2, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Publication number: 20200237648
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal, pulmonary and ophthalmic disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: July 19, 2019
    Publication date: July 30, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: ANKE STROYER, Carmen LOBBACK, Peter SERNO, Kia LOVIS, Philipp RUBENBAUER, Helko SCHIRMER, Danja GROßBACH, Tia JACOBS, Britta OLENIK, Julia Küsel, Donald BIERER
  • Publication number: 20200030270
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 30, 2020
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Kusel
  • Patent number: 10494372
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Philipp Rubenbauer, Daniel Götz, Danja Großbach, Franz-Josef Mais, Heiko Schirmer, Juergen Stiehl, Kai Lovis, Andreas Lender, Martin Seyfried, Theodor Zweifel, Maurus Marty, Günter Weingärtner
  • Publication number: 20180282337
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Application
    Filed: November 5, 2015
    Publication date: October 4, 2018
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg PETERS, Philipp RUBENBAUER, Daniel GÖTZ, Danja GROßBACH, Franz-Josef MAIS, Heiko SCHIRMER, Juergen STIEHL, Kai LOVIS, Andreas LENDER, Martin SEYFRIED, Theodor ZWEIFEL, Maurus MARTY, Günter WEINGÄRTNER
  • Publication number: 20130116443
    Abstract: The present invention relates to a process for the preparation of substituted 3-(2-hydroxyethyl)-1-[4-nitrophenyl]pyridin-2(1H)-ones which serve as important intermediate compounds for producing drugs.
    Type: Application
    Filed: April 26, 2011
    Publication date: May 9, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Joachim Krüger, Danja Grossbach, Holger Paulsen, Walter Kroh
  • Patent number: 8049035
    Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: November 1, 2011
    Assignee: Bayer Pharma AG
    Inventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
  • Patent number: 7994346
    Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: August 9, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Danja Grossbach, William Guilford, Michael Sander
  • Publication number: 20110124910
    Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
    Type: Application
    Filed: February 7, 2011
    Publication date: May 26, 2011
    Inventors: Tilo HAAG, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
  • Patent number: 7906678
    Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: March 15, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
  • Patent number: 7763743
    Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: July 27, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Danja Grossbach, William Guilford, Michael Sander
  • Publication number: 20090062558
    Abstract: The present invention relates to a new process for preparing estrogen-antagonistic 11?-fluoro-17?-alkylestra-1,3,5(10)-triene-3,17-diols of the general formula I having a 7?-(?-alkylamino-?-perfluoroalkyl)alkyl side chain and to ?-alkyl(amino)-?-perfluoro(alkyl)alkanes of the general formula II, to processes for their preparation and to the intermediates required for this purpose.
    Type: Application
    Filed: August 29, 2008
    Publication date: March 5, 2009
    Inventors: Michael SANDER, Danja Grossbach, Christian Dinter, Jorma Hassfeld, David Voigtlaender
  • Publication number: 20090036530
    Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.
    Type: Application
    Filed: June 30, 2008
    Publication date: February 5, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Klaus Bartel, Danja Grossbach, William J. Guilford, Michael Sander, Gabriele Winter
  • Publication number: 20080182897
    Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
    Type: Application
    Filed: December 3, 2007
    Publication date: July 31, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
  • Publication number: 20080182901
    Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.
    Type: Application
    Filed: December 3, 2007
    Publication date: July 31, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Klaus Bartel, Danja Grossbach, William J. Guilford, Michael Sander, Gabriele Winter
  • Publication number: 20070105949
    Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Application
    Filed: November 3, 2006
    Publication date: May 10, 2007
    Applicant: Schering Aktiengesellschaft
    Inventors: Danja Grossbach, William Guilford, Michael Sander
  • Publication number: 20060167025
    Abstract: The invention relates to tricyclic amino alcohols of general formula (I) method for synthesis of same and use of same as anti-inflammatory agents.
    Type: Application
    Filed: December 21, 2005
    Publication date: July 27, 2006
    Inventors: Markus Berger, Norbert Schmees, Heike Schaecke, Stefan Baurle, Hartmut Rehwinkel, Anne Mengel, Konrad Krolikiewicz, Danja Grossbach, David Voigtlaender